Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2020-05-11 Regulatory Filings
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 11, 2020, by Mustang Bio, Inc. It announces the issuance of a press release providing a corporate update and financial results for the first quarter ended March 31, 2020. The document itself does not contain the financial results or detailed financial statements but rather furnishes the press release as an exhibit. The length of the document is 3097 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (the press release) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain substantive financial data or the full earnings release text.
2020-05-11 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to a shareholder meeting. It includes information about voting methods, meeting details, election of directors, and proposals to be voted on. The presence of proxy materials and voting instructions clearly identifies this as a Proxy Solicitation & Information Statement. It is not an annual report, earnings release, or other financial report, but rather materials sent to shareholders to provide information and request votes for meetings, matching the definition of PSI.
2020-04-29 English
DEF 14A
Proxy Solicitation & Information Statement
2020-04-29 English
FORM 4
Director's Dealing
2020-04-29 English
FORM 4
Director's Dealing
2020-04-29 English
FORM 3
Director's Dealing
2020-04-29 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.